两药联用对糖尿病肾病患者血浆若干指标的影响

Effects of Two Drugs Combination on Plasma Indicators in Patients with Diabetic Nephropathy

目的：探讨阿魏酸钠联合缬沙坦治疗对糖尿病肾病患者血浆内皮素（ET）、一氧化氮（NO）、尿白蛋白排泄率（UAER）的影响。方法将123例糖尿病肾病患者随机分为阿魏酸钠治疗组（A 组）、缬沙坦治疗组（B 组）、阿魏酸钠＋缬沙坦联合治疗组（C 组），测定3组治疗前后血浆 ET、NO 及 UAER 的变化。结果 A组、B 组、C 组治疗前各项指标差异无统计学（P 〉0.05）；A 组、B 组治疗后血浆 ET 和 UAER 较治疗前均降低（P 〈0.05），血浆 NO 较治疗前均升高（P 〈0.05），C 组血浆 ET 和 UAER 较治疗前明显降低（P 〈0.01），血浆NO 较治疗前明显升高（P 〈0.01）。结论阿魏酸钠联合缬沙坦治疗可有效降低糖尿病肾病患者血浆 ET、UAER，升高 NO，对治疗糖尿病肾病有一定的作用。

Objective To investigate the effects of sodium ferulate and valsartan on Plasma endothelin（ET）,ni-tric oxide（NO）and urinary albumin excretion rate（UAER）in Patients with diabetic nePhroPathy. Methods 123 Pa-tients with diabetic nePhroPathy were randomly divided into sodium ferulate grouP（grouP A）,valsartan grouP（grouP B）as well as combination of sodium ferulate and valsartan grouP（grouP C）. Plasma ET,NO and UAER in the three grouPs were measured before and after treatment. Results There was no significant difference among indicators in grouP A,grouP B and grouP C before treatment（P 〉 0. 05）. Plasma ET and UAER were lower（P 〈 0. 05）and Plasma NO increased after treatment in grouP A and grouP B（P 〈 0. 05）. Plasma ET and UAER were significantly lower（P 〈0. 01）and Plasma NO significantly increased after treatment in grouP C（P 〈 0. 01）. Conclusion The combination of sodium ferulate and valsartan theraPy can effectively decrease Plasma ET and UAER as well as increase NO in Patients with diabetic nePhroPathy,which can be helPful for the treatment of diabetic nePhroPathy.